Roche Points To Pipeline Depth Beyond Oncology
This article was originally published in Pharmaceutical Approvals Monthly
At a late-stage pipeline review, Roche execs stressed the advances being made outside the company’s specialty focus on oncology, including neuroscience, inflammation and ophthalmology.
You may also be interested in...
Roche's Dry AMD Drug Lampalizumab Delivers Disappointment In Phase III
Analysts had already been doubtful about the prospects for success in the Spectri study. A second Phase III trial is ongoing, but the candidate is already being removed from revenue models.
Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech
CEO Raj Rai calls the transaction a “transformative event” for Akorn that will be instantly accretive and produce between $15 million and $20 million of run-rate synergies within 12 months. Acquisition of Hi-Tech adds prescription and OTC products, 18 filed ANDAs and increased manufacturing capability.
Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.